Zobrazeno 1 - 10
of 340
pro vyhledávání: '"Hirofumi HAMADA"'
Autor:
Hirofumi Hamada
Publikováno v:
ECNU Review of Education, Vol 2 (2019)
Purpose: This article examines the Japanese teaching profession’s position on current school governance reforms in Japan and the difficulties teachers are facing as the reforms progress. Design/Approach/Methods: This article describes how a policy
Externí odkaz:
https://doaj.org/article/ea8f28128369452b9c463a1bce36b370
Autor:
Toshinori Agatsuma, Yuki Abe, Masato Murakami, Yutaka Noguchi, Hirofumi Hamada, Miki Yamaguchi, Shu Takahashi, Riki Goto, Takashi Nakada, Sumie Muramatsu, Tomoko Shibutani, Tomoyo Honda, Tomomichi Fujitani, Reiko Kamei, Michiko Kitamura, Junko Yamaguchi, Tadashi Toki, Tetsuo Aida, Ken Sakurai, Tsuyoshi Karibe, Takanori Maejima, Satoru Yasuda, Daisuke Okajima
Supplementary Data from Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e1858eb2b81f8b7c3ad2bbf1d6159d0
https://doi.org/10.1158/1535-7163.22521904
https://doi.org/10.1158/1535-7163.22521904
Autor:
Hirofumi Hamada
Publikováno v:
Impact. 2021:15-17
Education reform helps ensure that the education in a given country is of the highest possible quality and is a key area of focus for many developed countries. Japan's education system rates highly and the evolution of education reform is key to ensu
Autor:
Hideaki Tahara, Yasuhiko Sasaki, Miki Yamaguchi, Tomoko Shibata, Ryota Hamasaki, Hiroaki Uchida, Masato Tanaka, Masaki Kojima, Hirofumi Hamada, Takuma Suzuki, Hitomi Ikeda, Yu Okubo, Kosaku Okuda, Mika Hamada-Uematsu
Publikováno v:
J Virol
Herpes simplex virus (HSV) is a promising tool for developing oncolytic virotherapy. We recently reported a platform for receptor-retargeted oncolytic HSVs that incorporates single-chain antibodies (scFvs) into envelope glycoprotein D (gD) to mediate
Autor:
Miki Yamaguchi, Reiko Kamei, Ken Sakurai, Tsuyoshi Karibe, Satoru Yasuda, Michiko Kitamura, Daisuke Okajima, Toshinori Agatsuma, Shu Takahashi, Tetsuo Aida, Sumie Muramatsu, Tomomichi Fujitani, Junko Yamaguchi, Hirofumi Hamada, Yutaka Noguchi, Takashi Nakada, Tomoyo Honda, Takanori Maejima, Masato Murakami, Tomoko Shibutani, Riki Goto, Yuki Abe, Tadashi Toki
Publikováno v:
Molecular cancer therapeutics. 20(12)
Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody–drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a
Autor:
Justus B. Cohen, Hirofumi Hamada, Hiroaki Uchida, Kenji Nakano, Hideaki Tahara, Joseph C. Glorioso, Heechung Kwon
Publikováno v:
Current Cancer Drug Targets. 18:162-170
Oncolytic virotherapy is a novel therapeutic modality for malignant diseases that exploits selective viral replication in cancer cells. Herpes simplex virus (HSV) is a promising agent for oncolytic virotherapy due to its broad cell tropism and the id
Autor:
Hirofumi Hamada, Rina Takayama, Katarzyna A. Podyma-Inoue, Katsuhito Fujiu, Akiko Kunita, Kazuki Takahashi, Teppei Morikawa, Hiroaki Uchida, Tetsuro Watabe, Hayato Okamoto, Shumpei Ishikawa, Masashi Fukayama, Moegi Sato, Yasuhiro Yoshimatsu, Tsukasa Oshima, Daisuke Komura, Taishi Tomizawa, Takeshi Fukuhara, Mao Komai
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Malignant melanoma is one of the untreatable cancers in which conventional therapeutic strategies, including chemotherapy, are hardly effective. Therefore, identification of novel therapeutic targets involved in melanoma progression is urgently neede
Autor:
Hiroaki Uchida, Kiminori Nakamura, Hirofumi Hamada, Yukari Nishii, Sachie Hirai, Haruka Aoki, Miki Yamaguchi, Yuji Sakuma
Publikováno v:
Biochemical and Biophysical Research Communications. 454:600-603
Antibody-drug conjugates (ADCs), drugs developed by conjugation of an anticancer agent to a monoclonal antibody (mAb), have lately attracted attention in cancer therapy because ADCs can directly bind cancer cells and kill them. Although mAbs for ADCs
Autor:
Mitsuo Tagaya, Hiroaki Uchida, Justus B. Cohen, Hitomi Ikeda, Hideaki Tahara, Tomoko Shibata, Hirofumi Hamada, Joseph C. Glorioso, Takuma Suzuki, Miki Yamaguchi, Aika Wakata, Yu Okubo
Membrane fusion, which is the key process for both initial cell entry and subsequent lateral spread of herpes simplex virus (HSV), requires the four envelope glycoproteins gB, gD, gH, and gL. Syncytial mutations, predominantly mapped to the gB and gK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d15c38489738dd93e0ed33cf3122d15
https://europepmc.org/articles/PMC5126368/
https://europepmc.org/articles/PMC5126368/
Autor:
Naoyuki Hasegawa, Masato Abei, Yuichi Obata, Koji Nakade, Kazunari K. Yokoyama, Rei Kawashima, Takeshi Yamada, Hirofumi Hamada, Ichinosuke Hyodo, Emiko Seo, Kuniaki Fukuda, Yuri Nakano
Publikováno v:
International Journal of Cancer. 133:1479-1488
Oncolytic viruses (OVs) are novel cancer therapeutics with great promise, but host antiviral immunity represents the hurdle for their efficacy. Immunosuppression by cyclophosphamide (CP) has thus been shown to enhance the oncolytic efficacy of many O